FULC
Price
$6.82
Change
+$0.22 (+3.33%)
Updated
Aug 15 closing price
Capitalization
368.9M
86 days until earnings call
IFRX
Price
$0.86
Change
+$0.03 (+3.61%)
Updated
Aug 15 closing price
Capitalization
58.46M
73 days until earnings call
Interact to see
Advertisement

FULC vs IFRX

Header iconFULC vs IFRX Comparison
Open Charts FULC vs IFRXBanner chart's image
Fulcrum Therapeutics
Price$6.82
Change+$0.22 (+3.33%)
Volume$516.85K
Capitalization368.9M
InflaRx
Price$0.86
Change+$0.03 (+3.61%)
Volume$197.88K
Capitalization58.46M
FULC vs IFRX Comparison Chart in %
Loading...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FULC vs. IFRX commentary
Aug 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FULC is a Hold and IFRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 18, 2025
Stock price -- (FULC: $6.82 vs. IFRX: $0.86)
Brand notoriety: FULC and IFRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FULC: 72% vs. IFRX: 65%
Market capitalization -- FULC: $368.9M vs. IFRX: $58.46M
FULC [@Biotechnology] is valued at $368.9M. IFRX’s [@Biotechnology] market capitalization is $58.46M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FULC’s FA Score shows that 1 FA rating(s) are green whileIFRX’s FA Score has 0 green FA rating(s).

  • FULC’s FA Score: 1 green, 4 red.
  • IFRX’s FA Score: 0 green, 5 red.
According to our system of comparison, FULC is a better buy in the long-term than IFRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FULC’s TA Score shows that 5 TA indicator(s) are bullish while IFRX’s TA Score has 6 bullish TA indicator(s).

  • FULC’s TA Score: 5 bullish, 5 bearish.
  • IFRX’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, IFRX is a better buy in the short-term than FULC.

Price Growth

FULC (@Biotechnology) experienced а +5.08% price change this week, while IFRX (@Biotechnology) price change was +7.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.78%. For the same industry, the average monthly price growth was +22.49%, and the average quarterly price growth was +23.13%.

Reported Earning Dates

FULC is expected to report earnings on Nov 12, 2025.

IFRX is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+8.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FULC($369M) has a higher market cap than IFRX($58.5M). FULC YTD gains are higher at: 45.106 vs. IFRX (-65.065). IFRX has higher annual earnings (EBITDA): -44.22M vs. FULC (-81.28M). FULC has more cash in the bank: 214M vs. IFRX (65.9M). IFRX has less debt than FULC: IFRX (703K) vs FULC (7.57M). IFRX has higher revenues than FULC: IFRX (130K) vs FULC (0).
FULCIFRXFULC / IFRX
Capitalization369M58.5M631%
EBITDA-81.28M-44.22M184%
Gain YTD45.106-65.065-69%
P/E RatioN/AN/A-
Revenue0130K-
Total Cash214M65.9M325%
Total Debt7.57M703K1,077%
FUNDAMENTALS RATINGS
FULC vs IFRX: Fundamental Ratings
FULC
IFRX
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
5165
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (23) in the null industry is somewhat better than the same rating for IFRX (56) in the Biotechnology industry. This means that FULC’s stock grew somewhat faster than IFRX’s over the last 12 months.

FULC's Profit vs Risk Rating (100) in the null industry is in the same range as IFRX (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to IFRX’s over the last 12 months.

FULC's SMR Rating (96) in the null industry is in the same range as IFRX (97) in the Biotechnology industry. This means that FULC’s stock grew similarly to IFRX’s over the last 12 months.

FULC's Price Growth Rating (51) in the null industry is in the same range as IFRX (65) in the Biotechnology industry. This means that FULC’s stock grew similarly to IFRX’s over the last 12 months.

FULC's P/E Growth Rating (100) in the null industry is in the same range as IFRX (100) in the Biotechnology industry. This means that FULC’s stock grew similarly to IFRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FULCIFRX
RSI
ODDS (%)
Bullish Trend 4 days ago
88%
N/A
Stochastic
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
79%
Momentum
ODDS (%)
Bearish Trend 4 days ago
81%
Bullish Trend 4 days ago
83%
MACD
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
85%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 6 days ago
88%
Bullish Trend 4 days ago
78%
Declines
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 11 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IFRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SROYF1.720.02
+1.36%
Sailfish Royalty Corp.
SIEGY136.841.04
+0.77%
Siemens AG
ERMAY6.20N/A
N/A
Eramet-SLN
MSMKF21.20N/A
N/A
Matsumotokiyoshi Holdings Co., Ltd.
CINGF0.07N/A
-2.65%
Coinsilium Group Ltd.

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with ANNX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then ANNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
+3.33%
ANNX - FULC
40%
Loosely correlated
+2.52%
VRDN - FULC
40%
Loosely correlated
+0.54%
RARE - FULC
39%
Loosely correlated
N/A
MRNA - FULC
38%
Loosely correlated
+4.98%
BMRN - FULC
38%
Loosely correlated
-0.79%
More

IFRX and

Correlation & Price change

A.I.dvisor tells us that IFRX and RCUS have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IFRX and RCUS's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IFRX
1D Price
Change %
IFRX100%
+4.30%
RCUS - IFRX
28%
Poorly correlated
+4.84%
VERA - IFRX
28%
Poorly correlated
+1.27%
NMRA - IFRX
26%
Poorly correlated
+3.16%
ARWR - IFRX
26%
Poorly correlated
+9.21%
FULC - IFRX
26%
Poorly correlated
+3.33%
More